Related Experiment Video

Updated: Dec 19, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice

Ambica Parmar1, Beate Sander2, Georg A Bjarnason3

  • 1Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada.

Critical Reviews in Oncology/Hematology
|June 5, 2020
PubMed

Insights

The treatment for metastatic renal cell carcinoma (mRCC) has many new options, but a lack of comparative data and rising costs create challenges for doctors and policymakers. Evidence is needed to guide choices and ensure cost-effectiveness for these advanced cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Health Policy

Background:

  • The treatment landscape for metastatic renal cell carcinoma (mRCC) has rapidly expanded with numerous systemic therapies.
  • This expansion presents challenges in selecting optimal treatments due to limited comparative data and increasing costs.

Purpose of the Study:

  • To review the current mRCC treatment landscape.
  • To highlight challenges in therapeutic choice for clinicians and health policy-makers.
  • To summarize existing evidence addressing these challenges.

Main Methods:

  • Literature review of systemic therapies for mRCC.
  • Analysis of comparative effectiveness and cost-effectiveness data.
  • Synthesis of evidence to inform clinical and policy decisions.

Main Results:

  • Significant increase in systemic therapy options for mRCC over the past decade.
  • Absence of direct comparative evidence across all available treatments.
  • Growing concern regarding the cost-effectiveness of novel mRCC therapies.

Conclusions:

  • Clinicians and health policy-makers face challenges in navigating the mRCC treatment landscape.
  • Further research and evidence generation are crucial for defining preferred therapies and ensuring value.
  • Addressing evidence gaps is essential for optimizing patient outcomes and managing healthcare resources.
Keywords:
Cost-benefit analysisImmunotherapyKidney neoplasmsReviewVascular endothelial growth factor antagonists & inhibitors

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K